SR One related stories
All articles and analysis
VC-backed RuiYi nets $4 mln from Silicon Valley BankSino-American biotech firm RuiYi has received $4 million in debt financing from Silicon Valley Bank. RuiYi's backers include 5AM Ventures, Versant Ventures, Apposite Capital, SR One and Merck Serono Ventures.
- Principia Biopharma nabs $50 mln Series B funds
Principia Biopharma has raised $50 million in Series B financing. Sofinnova Ventures led the round with participation from investors that include Morgenthaler Ventures, New Leaf Venture Partners, OrbiMed, SR One and Mission Bay Capital. In addition to the financing, Dr. Srinivas Akkaraju, a general partner at Sofinnova Ventures, has been added to Principia Biopharma's board of directors. Based in South San Francisco, Principia Biopharma is focused on developing small molecule drugs within the fields of autoimmune disease and oncology.
- Principia Biopharma nabs $50 mln Series B funds
Principia Biopharma has raised $50 million in Series B financing. Sofinnova Ventures led the round with participation from investors that include Morgenthaler Ventures, New Leaf Venture Partners, OrbiMed, SR One and Mission Bay Capital. In addition to the financing, Dr. Srinivas Akkaraju, a general partner at Sofinnova Ventures, has been added to Principia Biopharma's board of directors. Based in South San Francisco, Principia Biopharma is focused on developing small molecule drugs within the fields of autoimmune disease and oncology.
- IPO Profile: Applied Genetic Technologies Corp
Alta Partners, Intersouth Partners, InterWest Partners, Medimmune, Osage Partners and Sr One collectively hold 9,123,707 shares worth about $109 million at the IPO price.
- Alios BioPharma attracts $41 mln
Alios BioPharma has closed $41 million in Series B financing. Investors included Novo Ventures, SR One, Roche Venture Fund and Novartis Ventures. Based in South San Francisco, Alios BioPharma is a biotech firm focused on respiratory viral diseases.
- Alios BioPharma attracts $41 mln
Alios BioPharma has closed $41 million in Series B financing. Investors included Novo Ventures, SR One, Roche Venture Fund and Novartis Ventures. Based in South San Francisco, Alios BioPharma is a biotech firm focused on respiratory viral diseases.
- VC-backed AGTC debuts IPO
Florida-based biotech company Applied Genetic Technologies Corp. has launched its IPO after pricing its offering of over 4.16 million shares at $12 per share. The stock began trading Thursday on the NASDAQ under the ticker symbol "AGTC." BMO Capital Markets and Wedbush PacGrow Life Sciences are the lead underwriters. Its backers include InterWest Partners, Skyline Ventures, Intersouth Partners, MedImmune Ventures, Osage University Partners, SR One and Alta Partners.
- ZappRx raises $1 mln more in seed
ZappRx, which provides a platform for electronic prescriptions, announced it has raised $1 million in seed funding in a round led by Atlas Venture. The funding also included SR One, and individual investors Terry Meguid, David Hamamoto, Sean Trigony and James Glimm. The Cambridge, Mass.-based company has now raised $2.2 million in total seed financing, having announced /2013/09/e-prescription-platform-zapprx-closes-1-mln-seed-funding/ last fall a $1 million seed round.
- VC-backed vaccine developer Genocea Biosciences files for IPO
Genocea Biosciences has filed for an IPO. The number of shares that will be sold as well as pricing terms have yet to be decided. Citigroup and Cowen and Company will serve as lead underwriters. Based in Cambridge, Mass., Genocea Biosciences is a vaccine developer. Its backers include Polaris Venture Partners, Lux Capital Management, SR One, Cycad Group, Auriga Partners, Morningside Ventures, Johnson & Johnson Development Corporation, Skyline Ventures, Bill and Melinda Gates Foundation and MP Healthcare Venture Management.
- Aileron Therapeutics secures new financing
Aileron Therapeutics has secured $30 million in Series E equity financing from investors including Apple Tree Partners, Roche Venture Fund, Novartis Venture Funds, Lilly Ventures, SR One and Excel Venture Management. The clinical stage biopharmaceutical company is developing therapeutics based on its proprietary Stapled Peptide drug platform.